Oxford BioMedica, Boston University, Dana Farber Cancer Institute, Massachusetts General Hospital deal

The parties extended a 1997 agreement under which OXB received exclusive rights to a family of cytochrome P450 enzymes for use in cancer gene therapy with certain vectors (see BioCentury, Oct. 27, 1997). The extension covers the development of OXB's MetXia-P450 gene therapy product to treat pancreatic cancer. Under a 2000 extension, OXB received rights to additional vectors (see BioCentury, June 19, 2000).

MetXia, which uses the CYP2B6 cytochrome P450 gene, has completed Phase I/II testing for breast cancer and is in Phase I/II testing for pancreatic cancer. OXB expects to complete the Phase I portion of that trial this year. ...